Study of Reduced Dose of Menomune® in Children Who Previously Received Meningococcal Diphtheria Toxoid Conjugate Vaccine

Inclusion Criteria : * Stage I * Participant is healthy, as determined by medical history and physical examination. * Participant is at least 3 years of age but not yet 6 years of age at the enrolment. * For the TetraMenD group: received one dose of TetraMenD as a participant in trial 603-02 no less than 18 months prior to enrolment * For the Control group: no previous history of any meningococcal vaccination * Parent/Guardian has signed Institutional Review Board- (IRB-) approved informed consent form. * Stage II * Participant is healthy, as determined by medical history and physical examination. * Participant is at least 3 years of age but not yet 6 years of age at the time of enrollment in Stage 1. * Enrolled in the Control group only and received one dose of the reduced dose Menomune at Stage 1. * Parent/Guardian has signed Institutional Review Board- (IRB-) approved informed consent form. Exclusion Criteria : * Serious chronic disease (i.e., cardiac, renal, neurologic, metabolic, rheumatologic, psychiatric etc.) * Known or suspected impairment of immunologic function * Acute medical illness with or without fever within the last 72 hours or an axillary temperature (≥ 99.5ºF \[≥ 37.5ºC\]) at the time of inclusion * For Stage I, history of documented invasive meningococcal disease or previous meningococcal vaccination with exception of those participants recruited from Trial 603-02. * For Stage II, history of documented invasive meningococcal disease or participant did not receive Reduced-dose Menomune® six months prior. * Administration of immune globulin, other blood products within the last three months, injected or oral corticosteroids or other immunomodulatory therapy within six weeks of the study vaccine. Individuals on a tapering dose schedule of oral steroids lasting \< 7 days may be included in the trial as long as they have not received more than one course within the last two weeks prior to enrollment. * Antibiotic therapy within the 72 hours prior to vaccination or antibiotic therapy within the 72 hours prior to having any blood sample drawn * Received any vaccine in the 28-day period prior to study vaccination, or scheduled to receive any vaccination during the 28-day period after study vaccination in Stage 1 of the trial. * Suspected or known hypersensitivity to any of the vaccine components * Unavailable for the entire study period or unable to attend the scheduled visits or to comply with the study procedures * Enrolled in another clinical trial * Any condition, which, in the opinion of the investigator, would pose a health risk to the participant or interfere with the evaluation of the vaccine.